ArticleClinical rheumatology2025
Clinical value of salivary gland ultrasonography in evaluating secretory function, disease activity, and lymphoma risk factors in primary Sjögren's syndrome.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Managing Sjögren's Disease in Pediatric Patients.Paediatric drugs · 2026Review
- The Role of Imaging Techniques in the Evaluation of Extraglandular Manifestations in Patients with Sjögren's Syndrome.Diagnostics (Basel, Switzerland) · 2026Review
- Spatiotemporal orchestration of the salivary gland immune microenvironment in Sjögren's disease: a multidimensional framework of epithelial licensing, lymphoid neogenesis, and stromal remodeling.Frontiers in immunology · 2026Review
- Usefulness of salivary gland ultrasonography in Sjögren's syndrome: The Tunisian Experience.Clinical rheumatology · 2026Article
- Determinants and clinical correlates of minor salivary gland biopsy findings for suspected Sjögren disease: a single center retrospective analysis.Rheumatology international · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION/
objectivesSalivary gland ultrasonography (SGUS) has been investigated for its diagnostic usefulness in replacing invasive minor salivary gland biopsy (MSGB) in primary Sjögren's syndrome (pSS). However, its broader clinical value remains unclear. This study aimed to assess the clinical significance of SGUS in evaluating secretory function, disease activity, and lymphoma risk factors in pSS.
methodOne hundred fifty pSS patients who visited Seoul St. Mary's Hospital between January 2019 and July 2023 were included. Parameters related to secretory function, disease activity, and lymphoma risk factors were obtained. Associations between SGUS grades and secretory function or disease activity parameters were determined. Subgroup analyses based on SGUS grade or the presence of lymphadenopathy (LAP) in SGUS were also performed.
resultsSGUS grades correlated significantly with parameters of salivary gland secretory function and disease activity. Higher SGUS grades were associated with higher scores of overall EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI), ESSDAI glandular domain, EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) dryness domain, and physician or patient global assessment. Patients with the highest SGUS grade (overall score = 6) showed higher prevalence of laboratory risk factors or extraglandular manifestations related to lymphoma development than others. Detection of LAP by SGUS was associated with reduced salivary flow rates and higher ESSDAI, ESSPRI scores, and patient global assessments.
conclusionsOur results suggest that SGUS grades and the presence of LAP in SGUS findings are associated with clinical parameters representing secretory function and disease activity in pSS. High SGUS grades are associated with risk factors for lymphoma development. Key Points • SGUS grades showed significant correlations with clinical parameters related to salivary gland function and disease activity in patients with pSS. • pSS patients with the highest SGUS grade exhibited a higher prevalence of laboratory risk factors or extraglandular manifestations potentially related to lymphoma development compared to others. • These associations were more pronounced in the parotid gland than in the submandibular gland. • LAP identified by SGUS showed significant associations with clinical parameters related to the quality of life of patients with pSS.
Indexed as
Identifiers
40035924What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.